Summary
The aim of this study was to evaluate the medium term effects of the selective α1-adrenenergic-blocker terazocin on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was give orally for 30 days. The daily dose was 1 mg for the first 7 days, 2mg for the next 7 days and 5mg for the remaining period of this clinical trial. At the end of this clinical trial, plasma ANP levels increased by 16.40% despite the drop in blood pressure while left atrial and ventricular diameters remained unchanged. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical load on the left cardiac chambers but the result of a pharmacological action. These observations also indicate that terazocin exerts part of its antihypertensive action by increasing ANP plasma levels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papadopoulos C.L., Kokkas B, Kotridis P, Gitsios C, Sakadamis G, Kanonidis I, Faitatziadis D, Pilis A, Theodoridis E, Paradelis A. (1995): Plasma atrial natriuretic peptide in essential hypertension after angiotensin coverting enzyme inhibition. Intern. J. Angiology, 4, 44–45
Papadopoulos C.L., Kokkas B, Kotridis P, Kanonidis I., Kyriakou P, Poulantzas N, Kotoula M, Paradelis A. (1995): The effect of β1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Intern. J. Angiology, 4, 165–168
Papadopoulos C.L, Kokkas B, Kotridis P, Karamouzis M, Haldoupi A, Platis A, Dadous G. (1998): The effect of β1-blocker/β2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc. Drugs Ther., 12,345–346
Papadopoulos C.L, Kokkas B, Anogiannakis G. (2000): Beta blockers and atrial natriuretic peptide (ANP) in hypertension. Intern. J. Immunopathol. Pharmacol., 13,107–110
Kotridis P, Kokkas B., Karamouzis M., Sakadamis G., Kanonidis I., Dadous G., Karadona G., Gouli O., Karadoumanis J, Papadopoulos P.C., Papadopoulos C.L. (2002): Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. Blood Pressure, 11,91–94,
Kyncl J. (1993) Pharmacology of terazocin: an αlpha1—selective blocker. J. Clin. Pharmacol., 33, 878–888
Hama J, Nagata S, Takenaka T, Kino S, Shimada M, Horiuchi M, Katori R.I. (1995): Atrial natriuretic peptide and antihypertensive action due to beta — blockade in essential hypertensive patients. Angiology, 46, 511–516
Kokkas B, Kotridis P, Karamouzis M, Kanonidis I, Sakadamis G, Dadous G, Haritos S, Kyriakou P, Theodossiadis I, Papadopoulos P.C, Mirtsou-Fidani V, Papadopoulos C.L. (2002): Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil. Eur. J. Drug Metab. Pharmacokin., 27, 45–48.
Iwasaki T, Niwa A, Shinoda T, Ishihara M, Aizawa T, Yamada T. (1989): Effects of calcium antagonists and nitroglycerin on atrial natriuretic peptide in normal subjects and patients with essential hypertension. Angiology, 40,24–28
Hollenberg M, Plum J, Heering P, Kutkuthn H, Grabensee B. (1991): Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J. Hypertension, 9,819–824
Geller D, Currie M, Wakitani K (1984): Atriopeptides. Biochem. Biophys. Res. Commun., 120,333–338
Rosmalen F, Horman J, Tan A. (1988): A sensitive redioimmunoassay of atrial natriuretic peptide in human plasma; some guidelines for clinical applications. Z. Kardiol. 1988, 77 (Suppl.2),20–25
Karamouzis M, Mandroukas K, Deligiannis D (1994): Changes in atrial natriuretic peptide (a-ANP) in long distance swimmers. Clin. Chem. Enzym. Comms., 6,191–195
Shields P, Glembotski C (1989): Regulation of atrial natriuretic factorsecretion from neonatal rat primary atrial cultures by activators of protein kinases A and C. Biol. Chem., 264,9322–9328
Semplicini A, Valle R, Serena L, Fazari G, Fontebasso A, Gebbin A, De Toni R, Pessina A. (1994). Long-term alpha-1 adrenoceptor blockade does not affect plasma atrial natriuretic peptide in hypertensive patients. Horm. Metab. Res., 26,207–208
Valle R, Semplicini A, Serena L, Gebbin A, Fontebasso A, Gerardi G, De Toni R, Pessina A (1996): Pressure and metabolic effects of terazocin in essential hypertension. Cardiologia, 39,421–424
Yoshimoto T, Naruse M, Naruse K, Shionoya K, Tanaka M, Tanave A, Hagiwara H, Hirose S, Muraki T, Demusa H. (1996): Angiotensin II-depended down regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats. Endocrinology, 137,1102–1107
Yoshimoto T, Naruse M, Irie K, Tanabe A, Seki T, Tanaka M, Imaki T Naruse K, Muraki T, Matsuda Y, Demura H (1998): Beta-adrenergic antagonist propranolol potentiates hypertensive action of natriuretic peptides. Eur. J. Pharmacol., 12,61–66
Yoshimoto T, Naruse M, Tanabe A, Naruse A, Seki T, Imaki T, Muraki T, Matsuda Y, Damura H (1998): Potentiation of natriuretic peptide action by beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology, 139,81–88.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kotridis, P., Kokkas, B., Kyriakou, P. et al. Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin. Eur. J. Drug Metab. Pharmacokinet. 28, 143–146 (2003). https://doi.org/10.1007/BF03190503
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190503